KRAS and pancreatic neoplasm: KRas-induced activation of ERK, the main effector of the MAPK-ERK pathway, is thought to be responsible for a host of tumorigenic properties including tumor cell chemoresistance, invasion of pancreatic tumors, and the proliferation of pancreatic tumor cells [256].